autologous monocyte
Recently Published Documents


TOTAL DOCUMENTS

12
(FIVE YEARS 5)

H-INDEX

4
(FIVE YEARS 1)

2020 ◽  
Vol 104 (S3) ◽  
pp. S199-S199
Author(s):  
Ji yun Jang ◽  
Thuy Nguyen Phuong ◽  
Jung sik Kim ◽  
Chung Gyu Park
Keyword(s):  

2020 ◽  
Vol 69 (3) ◽  
pp. 477-488 ◽  
Author(s):  
Steve Boudewijns ◽  
Martine Bloemendal ◽  
Nienke de Haas ◽  
Harm Westdorp ◽  
Kalijn F. Bol ◽  
...  

Author(s):  
Shigetaka Shimodaira ◽  
Ryu Yanagisawa ◽  
Terutsugu Koya ◽  
Koichi Hirabayashi ◽  
Yumiko Higuchi ◽  
...  

Significant recent advances in cancer immunotherapeutics include the vaccination of cancer patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines with homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, the yield of autologous monocyte-derived DCs varies in each patient. Priming with a low dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16–18 h prior to apheresis resulted in 50% more harvested monocytes, with a significant increase in the ratio of CD11c+CD80+ DCs/apheresed monocytes. The detection of antigen-specific cytotoxic T lymphocytes after Wilms’ tumor 1-pulsed DC vaccination was higher in patients treated with rhG-CSF than those who were not, based on immune monitoring using tetramer analysis. Our study is the first to report that DC vaccines for cancer immunotherapy primed with low-dose rhG-CSF are expected to achieve higher acquired immunogenicity.


2016 ◽  
Vol 34 (12) ◽  
pp. 1330-1338 ◽  
Author(s):  
Sofie Wilgenhof ◽  
Jurgen Corthals ◽  
Carlo Heirman ◽  
Nicolas van Baren ◽  
Sophie Lucas ◽  
...  

Purpose Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pretreated advanced melanoma. Ipilimumab, an immunoglobulin G1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated protein 4 receptor that counteracts physiologic suppression of T-cell function, improves the overall survival of patients with advanced melanoma. This phase II study investigated the combination of TriMixDC-MEL and ipilimumab in patients with pretreated advanced melanoma. Patients and Methods Thirty-nine patients were treated with TriMixDC-MEL (4 × 106 cells administered intradermally and 20 × 106 cells administered intravenously) plus ipilimumab (10 mg/kg every 3 weeks for a total of four administrations, followed by maintenance therapy every 12 weeks in patients who remained progression free). Six-month disease control rate according to the immune-related response criteria served as the primary end point. Results The 6-month disease control rate was 51% (95% CI, 36% to 67%), and the overall tumor response rate was 38% (including eight complete and seven partial responses). Seven complete responses and one partial tumor response are ongoing after a median follow-up time of 36 months (range, 22 to 43 months). The most common treatment-related adverse events (all grades) consisted of local DC injection site skin reactions (100%), transient post–DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13%), hypophysitis (15%), and diarrhea/colitis (15%). Grade 3 or 4 immune-related adverse events occurred in 36% of patients. There was no grade 5 adverse event. Conclusion The combination of TriMixDC-MEL and ipilimumab is tolerable and results in an encouraging rate of highly durable tumor responses in patients with pretreated advanced melanoma.


2011 ◽  
Vol 52 (6) ◽  
pp. 990 ◽  
Author(s):  
Dae Suk Kim ◽  
Dong Hyun Kim ◽  
Boncheol Goo ◽  
Young Hun Cho ◽  
Jin Mo Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document